EUCTR2016-001119-19-Outside-EU/EEA进行中（未招募）不适用
Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Generally healthy male or female subject, aged 12 to 17 years, who required outpatient treatment for an acute pharyngitis/tonsillitis infection that was appropriate to treat with oral azithromycin.
- •2. Subjects must have had a positive rapid antigen detection test (RADT) at baseline.
- •3. Subject was sighted in both eyes and has no known history of any clinically significant eye disease or condition, apart from a need for corrective lenses.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 30
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide antibiotic.
- •2. Subjects who had taken another antibiotic within the previous 3 days, or had taken azithromycin (any formulation, including sustained release) within the past 4 weeks.
- •3. Subjects with clinical evidence or current/past history of: impaired hepatic or renal function; clinically significant congenital or acquired cardiac disease including cardiac rhythm disorders; myasthenia gravis or other significant neuromuscular disorder; or any other disease or condition that could have put the subject at increased risk for injury if he/she participated in the study.
- •4. Subjects with increased risk of QT prolongation, including known personal or family history of prolonged QT syndrome, serious ventricular arrhythmia or family history of sudden cardiac death; subjects currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of classes IA and III and antipsychotic agents, antidepressants and fluoroquinolones; subjects with electrolyte disturbance, particularly in cases of hypokalemia and hypomagnesemia; subjects with clinically relevant bradycardia, cardiac arrhythmia or cardiac insufficiency.
- •5. Subjects with chronic diseases of the gastrointestinal tract which might have either adversely affected absorption of the drug and/or put the subject at increased risk for injury in the event antibiotic associated diarrhea or similar illness occurred.
- •6. Subjects with a medical condition at baseline that required concomitant treatment with a drug known to have effects on vision (ie, a drug whose package insert reported pharmacologic effects on the eye or contained any specific warning of possible adverse effects on the eye or vision based on clinical study results).
研究者
相似试验
已完成
2 期
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)BlepharitisNCT00894530Merck Sharp & Dohme LLC314
已完成
2 期
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment PeriodBlepharitisNCT00892970Merck Sharp & Dohme LLC313
已完成
不适用
Clinical trial on the effect of Azyter in patients with blepharitis.BlepharitisNL-OMON2008930
尚未招募
3 期
The effect of azithromycin 1 on the signs and symptoms of blepharitisBlepharitis.H01.0BlepharitisIRCT20190618043934N9Birjand University of Medical Sciences45
已完成
不适用
The efficacy of azithromycin eye drops on the findings around the eyelids of patients with blepharitisblepharitisJPRN-UMIN000044348Shimazaki eye clinic/Tokyo Dental College Ichikawa General Hospital30